BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has scheduled a conference call for 5th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.biomarin.com
Earnings Expectation
BioMarin Pharmaceutical Inc. is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter income of $ 1.29 per share from revenue of $ 454.64 million. Looking ahead, the full year income are expected at $ 4.19 per share on the revenues of $ 1859.54 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,850.00 million ~ $ 1,950.00 million
Click Here For More Historical Outlooks Of BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The companys commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome.
